SEARCH

SEARCH BY CITATION

References

  • 1
    Ciechanover A, Elias S, Heller H, Ferber S, Hershko A. Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes. J Biol Chem 1980; 255: 75258.
  • 2
    Hershko A, Ciechanover A, Rose I A. Identification of the active amino acid residue of the polypeptide of ATP-dependent protein breakdown. J Biol Chem 1981; 256: 15258.
  • 3
    Schlesinger D H, Goldstein G, Niall H D. The complete amino acid sequence of ubiquitin, an adenylate cyclase stimulating polypeptide probably universal in living cells. Biochemistry 1975; 14: 22148.
  • 4
    Rechsteiner M. Ubiquitin-mediated pathways for intracellular proteolysis. Annu Rev Cell Biol 1987; 3: 130.
  • 5
    Hershko A. Ubiquitin-mediated protein degradation. J Biol Chem 1988; 263: 1523740.
  • 6
    Hershko A, Heller H, Eytan E, Reiss Y. The protein substrate-binding site of the ubiquitin-protein ligase system. J Biol Chem 1986; 261: 119929.
  • 7
    Ciechanover A, Schwartz A L. How are substrates recognized by the ubiquitin-mediated proteolytic system? Trends Biochem Sci 1989; 14: 4838.
  • 8
    Jentsch S, Seufert W, Sommer T, Reins H A. Ubiquitin- conjugating enzymes: novel regulators of eukaryotic cells. Trends Biochem Sci 1990; 15: 1958.
  • 9
    Hershko A. The ubiquitin pathway for protein degradation. Trends Biochem Sci 1991; 16: 2658.
  • 10
    Rechsteiner M. Natural substrates of the ubiquitin proteolytic pathway. Cell 1991; 66: 6158.
  • 11
    Pickart C M. Ubiquitin enters the new millennium. Mol Cell 2001; 8: 499504.
  • 12
    Schlesinger M J, Hershko A, eds. The Ubiquitin System. Cold Spring Harbor, NY. Cold Spring Harbor Laboratory.
  • 13
    Haas A L, Warms J V, Hershko A, Rose I A. Ubiquitin-activating enzyme. Mechanism and role in protein-ubiquitin conjugation. J Biol Chem 1982; 257: 25438.
  • 14
    Galloway P G, Likavec M J. Ubiquitin in normal, reactive and neoplastic human astrocytes. Brain Res 1989; 500: 34351.
  • 15
    Kanayama H, Tanaka K, Aki M, et al. Changes in expressions of proteosome and ubiquitin genes in human renal cancer cells. Cancer Res 1991; 51: 667785.
  • 16
    Ishibashi Y, Takada K, Joh K, Okawa K, Aoki T, Matsuda M. Ubiquitin immunoreactivity in human malignant tumors. Br J Cancer 1991; 63: 3202.
  • 17
    Marin F, Cheng Z, Kovacs K. Ubiquitin immunoreactivity in corticotrophs following glucocorticoid treatment and in pituitary adenomas. Arch Pathol Laboratory Med 1993; 117: 2548.
  • 18
    Osada T, Sakamoto M, Nishibori H, et al. Increased ubiquitin immunoreactivity in hepatocellular carcinomas and pre-cancerous lesions of the liver. J Hepatol 1997; 26: 126673.
  • 19
    Liebman H A, Furie B C, Tong M J, et al. Des-r-carboxy prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 142731.
  • 20
    Tamano M, Sugaya H, Oguma M, et al. Immuno- localisation of PIVKA-II in paraffin-embedded specimens of hepatocellular carcinoma. Liver 1999; 19: 40610.
  • 21
    Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 45781.
  • 22
    Pagano M, Tam S W, Theodoras A M, et al. Role of the ubiquitin-proteosome pathway in regulating abundance of the cyclin-dependent kinase inhibitor P27. Science 1995; 269: 682.
  • 23
    Shirane M, Harumiya Y, Ishida N, et al. Down-regulation of P27 Kip1 by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 1999; 274: 13886.
  • 24
    Nakayama K, Nakayama K. Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development. Biossays 1998; 20: 1020.
  • 25
    Deanna M, Koepp J, Harper W, Elledge S J. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 1999; 97: 4314.
  • 26
    Salghetti S E, Muratani M, Wijnen H, Futcher B, Tansey W P. Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proc Nat Acad Sci USA 2000; 97: 311823.
  • 27
    Grigioni W F, D'Errico A, Bacci F, et al. Primary liver neoplasms: evaluation of proliferative index using Moab Ki67. J Pathol 1989; 158: 239.
  • 28
    King K L, Hwang J J, Chau G Y, et al. Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1998; 13: 2739.